Skip to content

Studying the effect of different doses of Tadalafil on semen parameters

Studying the effect of different doses of Tadalafil on semen parameters-a clinical trial study

Status
Recruiting
Phases
Early Phase 1
Study type
Interventional
Source
IRCT
Registry ID
IRCT20250921067309N1
Enrollment
108
Registered
2025-10-23
Start date
2025-11-11
Completion date
Unknown
Last updated
2025-12-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Erectile dysfunction. Diseases of the genitourinary system

Interventions

Intervention group: Patients are randomly assigned to three groups in a block-wise manner, and tadalafil (Exir Pharmaceutical Company - Iran) doses of 5, 10, and 20 mg are given to patients once a day

Sponsors

Arak University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
Male
Age
18 Years to 40 Years

Inclusion criteria

Inclusion criteria: Diagnosis of erectile dysfunction 18 to 40 years old The sample should be collected between 2 and 5 days after the last ejaculation. No underlying disease (heart disease, diabetes, blood pressure, liver disease, kidney disease) Abstaining from alcohol and drugs Not taking medications for neurological and psychiatric diseases

Exclusion criteria

Exclusion criteria: Non-cooperation

Design outcomes

Primary

MeasureTime frame
Semen analysis parameters. Timepoint: Semen analysis in the group of patients taking 5 mg tadalafil tablets, patients taking 10 mg tadalafil tablets, and patients taking 20 mg tadalafil tablets. Method of measurement: Semen analysis test.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactRasoul Jafari Arismani

Arak University of Medical Sciences

pr_valieasr@arakmu.ac.ir+98 86 3222 2003

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026